Immunic Secures European Patent for Vidofludimus Calcium Dosing

Immunic, a biotechnology firm, announced the grant of a European patent providing broad protection for vidofludimus calcium dosing regimens. The patent covers all indications, including multiple sclerosis, and extends protection to all forms of the drug. This follows a similar patent granted by the USPTO in 2023.

The patent strategy strengthens Immunic's exclusivity on vidofludimus calcium in Europe until at least 2038, with potential extensions to 2043 through a Supplementary Protection Certificate. The coverage encompasses all salt, solvate, and free acid forms of the drug, bolstering its global intellectual property framework.

The patent complements several granted patents in the US and other regions, aiming to ensure long-term market exclusivity for vidofludimus calcium. This development is pivotal as the drug undergoes late-stage trials for multiple sclerosis.